A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC

A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC

This study describes the design of the TARGET‐hepatocellular carcinoma (HCC) cohort and descriptive characteristics of the patient population at diagnosis among those who were enrolled in the cohort across academic and community clinical centers. TARGET‐HCC is a 5‐year, longitudinal, observational c...

Full description

Bibliographic Details
Main Authors:	Roniel Cabrera, Amit G. Singal, Massimo Colombo, R. Kate Kelley, Hannah Lee, Andrea R. Mospan, Tim Meyer, Pippa Newell, Neehar D. Parikh, Bruno Sangro, K. Rajender Reddy, Stephanie Watkins, Richard C. Zink, Adrian M. Di Bisceglie
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2021-03-01
Series:	Hepatology Communications
Online Access:	https://doi.org/10.1002/hep4.1652

Similar Items

The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma.
by: Neehar D Parikh, et al.
Published: (2016-04-01)

Cost-effectiveness of a biomarker-based screening strategy for hepatocellular carcinoma in patients with cirrhosis
by: Amit G. Singal, et al.
Published: (2024-06-01)

A Dual‐Filtration System for Single‐Cell Sequencing of Circulating Tumor Cells and Clusters in HCC
by: Vincent L. Chen, et al.
Published: (2022-06-01)

A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation
by: Yu Lin, et al.
Published: (2022-03-01)

Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosisResearch in context
by: Szu-Yu Zoe Kao, et al.
Published: (2024-09-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Cost-effectiveness of an outreach program for HCC screening in patients with cirrhosis: a microsimulation modeling studyResearch in context
by: Tami Gurley, et al.
Published: (2025-03-01)

Decision making in elderly HCC
by: Mosca F, et al.
Published: (2011-08-01)

Qualitative and Quantitative Assessment of Enhancement and Washout Characteristics of HCC and non HCC Hypervascular Liver Tumours
by: Prerna Garg, et al.
Published: (2018-02-01)

Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization
by: Osman Öcal, et al.
Published: (2024-04-01)

Comparison of a multitarget blood test to ultrasound and alpha‐fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta‐analysis
by: Amit G. Singal, et al.
Published: (2022-10-01)

Immunotherapy for HCC: limitations in patients with NASH
by: Parul D. Agarwal, et al.
Published: (2023-03-01)

Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC
by: Yulong Wei, et al.
Published: (2021-01-01)

An Evidence-Based Multidisciplinary Approach to the Management of Hepatocellular Carcinoma (HCC): The Alberta HCC Algorithm
by: Kelly W Burak, et al.
Published: (2010-01-01)

Cryptogenic non-cirrhotic HCC: Clinical, prognostic and immunologic aspects of an emerging HCC etiology
by: Boris J. B. Beudeker, et al.
Published: (2024-02-01)

Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
by: Na Sun, et al.
Published: (2020-09-01)

Combined hepatocellular-cholangiocarcinoma (cHCC-CC): a distinct entity
by: Kate O’Connor, et al.
Published: (2014-05-01)

HCC: RNA-Sequencing in Cirrhosis
by: Haoyu Wang, et al.
Published: (2023-01-01)

HCC Biomarkers in China and Taiwan
by: Regina M. Santella
Published: (2007-02-01)

Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC?
by: Giuseppina Vizioli, et al.
Published: (2025-02-01)

Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy
by: Tongdi Fang, et al.
Published: (2022-05-01)

Evaluation of fibrosis in cirrhotic elderly patients with HCC
by: Portale TR, et al.
Published: (2011-08-01)

Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis
by: Patrick Marquardt, et al.
Published: (2021-09-01)

Comparison between using hepatocellular carcinoma (HCC) risk scores and the HCC national guideline to identify high‐risk chronic hepatitis B patients for HCC surveillance in Thailand
by: Chitchai Rattananukrom, et al.
Published: (2022-06-01)

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
by: Andrew M. Brown, et al.
Published: (2023-02-01)

A Rationale and Framework for Digital Literacies in Legal Education
by: Kate Galloway
Published: (2017-01-01)

Hepatocellular carcinoma (HCC) masquerading as hilar cholangiocarcinoma: An unusual presentation of jaundice
by: Rohit O Mundhada, et al.
Published: (2023-01-01)

From MASLD to HCC: What's in the middle?
by: Alessia Provera, et al.
Published: (2024-08-01)

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
by: Fuat Bicer, et al.
Published: (2023-11-01)

Contrast Enhanced MRI in the Diagnosis of HCC
by: Eric Niendorf, et al.
Published: (2015-09-01)

Imaging of HCC—Current State of the Art
by: Christina Schraml, et al.
Published: (2015-11-01)

How to improve HCC surveillance outcomes
by: Morris Sherman
Published: (2019-12-01)

Exposure of Bisphenols (BPs) to hepatocellular carcinoma (HCC) patients and non-HCC patients: Association with liver function biomarkers
by: Shibo Li, et al.
Published: (2024-12-01)

Investigating the Genetic Diversity of Hepatitis Delta Virus in Hepatocellular Carcinoma (HCC): Impact on Viral Evolution and Oncogenesis in HCC
by: Horng-Heng Juang, et al.
Published: (2024-05-01)

Non-contrast short MRI surveillance for HCC screening: the study protocol of the SMS-HCC prospective multicenter study
by: Céline van de Braak, et al.
Published: (2024-03-01)

Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC
by: Hyo Jung Cho, et al.
Published: (2021-07-01)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
by: Yan Huang, et al.
Published: (2022-06-01)

The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications
by: Muhammad Sajid, et al.
Published: (2022-05-01)

FIB-4 and APRI for cirrhosis detection in a privately insured national cohort
by: Neehar D. Parikh, et al.
Published: (2024-01-01)

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
by: Max Seidensticker, et al.
Published: (2023-05-01)